Iovance Biotherapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Narrows
Iovance Biotherapeutics reported significant revenue growth for the nine months ended September 30, 2026, reaching $292.2 million compared to $176.7 million in the prior year. The company successfully narrowed its net loss to $148.6 million from $319.1 million, supported by reduced research and development expenses and increased product sales.
- Key figure
- Net loss $22.3M